Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Liver cancer is one of the most lethal malignant cancers worldwide. However, the therapeutic options for advanced liver cancers are limited and reveal scant efficacy. The current study investigated the effects of nivolumab (Niv) and escitalopram oxalate (Esc) in combination on proliferation of liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Vincent Chin-Hung, Huang, Shao-Lan, Huang, Jing-Yu, Hsu, Tsai-Ching, Tzang, Bor-Show, McIntyre, Roger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454364/
https://www.ncbi.nlm.nih.gov/pubmed/37628813
http://dx.doi.org/10.3390/ijms241612630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454364/
https://www.ncbi.nlm.nih.gov/pubmed/37628813
http://dx.doi.org/10.3390/ijms241612630

Ejemplares similares